Table 3:
HIV-infected young MSM and transwomen in Atlanta, GA 2009–2016, Association between anal cytology and demographic, behavioral and clinical factors
| Characteristics, N (%) | ASC-H/cHSIL N=27 (a) |
cLSIL N=107 (b) |
ASCUS N=103 (c) |
Negative N=12 (d) |
Omnibus P-value |
Pairwise Comparisons |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Race | ||||||
| African American | 27 (100%) | 103 (96%) | 92 (89%) | 12 (100%) | 0.100 | |
| Other | 0 (0%) | 4 (4%) | 11 (11%) | 0 (0%) | ||
| Gender of sex partners | ||||||
| Men only | 25 (93%) | 84 (79%) | 78 (76%) | 10 (83%) | 0.280 | |
| Men and women | 2 (7%) | 23 (22%) | 25 (24%) | 2 (17%) | ||
| Education, n=243 | ||||||
| High School or Less | 11 (42%) | 54 (51%) | 53 (53%) | 7 (58%) | 0.755 | |
| College | 15 (58%) | 51 (49%) | 47 (47%) | 5 (42%) | ||
| Behavioral | ||||||
| Age at coitarche, mean (SD) | 14.9 (3.5) | 14.9 (2.8) | 14.4 (3.6) | 15 (3.9) | 0.736 | |
| Intercourse | ||||||
| Both + Receptive Only | 26 (96%) | 104 (97%) | 102 (99%) | 11 (92%) | 0.203 | |
| Insertive Only | 1 (4%) | 3 (3%) | 1 (1%) | 1 (8%) | ||
| Number of Partners | ||||||
| 1 to 5 | 7 (33%) | 11 (12%) | 22 (25%) | 1 (9%) | 0.044* | b ≠ c |
| 6 to 10 | 5 (24%) | 31 (35%) | 18 (20%) | 3 (27%) | ||
| 11 to 20 | 4 (19%) | 18 (20%) | 8 (9%) | 2 (18%) | ||
| 21 or more | 5 (24%) | 29 (33%) | 41 (46%) | 5 (46%) | ||
| Abuse, n=175 | ||||||
| Yes | 7 (37%) | 19 (25%) | 23 (32%) | 4 (57%) | 0.276 | |
| No | 12 (63%) | 57 (75%) | 50 (69%) | 3 (43%) | ||
| Transactional Sex, n=143 | ||||||
| Yes | 4 (22%) | 14 (26%) | 8 (12%) | 3 (60%) | 0.038* | c ≠ d |
| No | 14 (78%) | 41 (75%) | 57 (88%) | 2 (40%) | ||
| Tobacco Use | 8 (30%) | 39 (37%) | 36 (35%) | 6 (50%) | 0.670 | |
| Marijuana Use | 13 (48%) | 71 (66%) | 60 (58%) | 8 (67%) | 0.301 | |
| Marijuana and alcohol use | 10 (37%) | 56 (52%) | 50 (49%) | 5 (42%) | 0.518 | |
| History of rectal STIs | 15 (56%) | 59 (57%) | 58 (57%) | 4 (36%) | 0.599 | |
| Clinical | ||||||
| Age at cytology, mean (SD) | 20.9 (2.0) | 20.2 (2.0) | 20.3 (2.1) | 19.8 (2.3) | 0.394 | |
| CD4 Countsa | ||||||
| At baselineb, mean (95% CI) | 230 (150 – 327) | 257 (205 – 315) | 302 (255 – 353) | 223 (168 – 286) | 0.160 | |
| At cytology, mean (95% CI) | 317 (254 – 387) | 325 (282 – 371) | 389 (345 – 436) | 424 (355 – 499) | 0.034* | a ≠ d, b ≠ c, b ≠ d |
| Viral Loads | ||||||
| At baseline, median (IQR) | 46,440 (20,600 – 172,080) |
37,080 (12,300 – 155,612) |
57,362 (9,580 – 232,760) |
36,845 (19,160 – 109,329) |
0.854 | |
| At cytology, median (IQR) | 40 (40 – 10,563) | 153 (40 – 21,220) | 109 (40 – 16,418) | 40 (40 – 1,000) | 0.218 | |
| At cytology, # UDc (%) | 15 (56%) | 43 (41%) | 47 (47%) | 7 (64%) | 0.303 | |
| Number of HPV vaccines | ||||||
| 0 | 26 (96%) | 92 (86%) | 86 (84%) | 8 (67%) | 0.100 | |
| 1 or more | 1 (4%) | 15 (14%) | 17 (17%) | 4 (33%) | ||
| Anal Warts, n=240 | ||||||
| Yes | 9 (35%) | 61 (59%) | 42 (42%) | 4 (40%) | 0.041* | a ≠ b, b ≠ c |
| No | 17 (65%) | 43 (41%) | 58 (58%) | 6 (60%) | ||
a
CD4s regression modeled as square root of CD4, presented squared for interpretation purposes
b
Baseline indicates at the time of HIV diagnosis
c
UD: Undetectable